SelfActivating Viridin SAV Prodrug for Ovarian Cancer

1
Self-Activating Viridin (SAV) Pro-drug for
Ovarian Cancer

• Commercializing Science HBS 2008
• Yvonne Lee
• Ning Lu
• Max Morgan
• Tjorvi Perry
• Chris Wilson-Byrne 
•                 

2
Ovarian Cancer

• The Silent Killer
• 2nd most common gynecologic malignancy
• 5th leading cause of death in women
• Surgical and Platinum-based therapy as first-line
  treatment
• High rate of recurrence
• Surgery is not an option
• Many are Platinum-resistant

3
Self-Activating Viridin (SAV)

• PI3 Kinases
• Enzymes that control cell growth
• Drives many cancers
• Wortmannin inhibits PI3K
• 1/2-life too short
• Highly toxic in humans
• Self-Activating Viridin (SAV)
• Self-activates to Wortmannin
• Slow, sustained release
• Favorable half-life
• Fast-acting
• Less toxic
• IP/IV Delivery
• Effective in animal models

4
Intellectual Property

• Patent Application Pending
• Invention
• W-L-T ? W
• T Dextran
• Prior Art
• Freedom to Operate

5
Development and Market Potential Requires
Focused Strategy
Relative high development cost and high market
risk require more proof of concept data for this
molecule to move to next stage, especially under
current economic environment
Focus on Proof of Concept
Decision Resources Ovarian Cancer Report Dec
2007
6
Recommendations

• Single Product/ Single Market Strategy
• Complete Pre-Clinical Studies in Animals
• Efficacy studies and toxicity studies 2-3 years
• 2M in funding, possible sources
• Foundation gt Federal gt Commercial
• Venture Capital and Angel Investors

7
Appendix
8
Project Interviews
9
Future Potential

• Entering a challenging Market
• Number of kinase inhibitors for big five tumors
• Markets already highly consolidated

10
Direct Competition

• PI3 Kinase inhibitors in trials